Tripair - Rob ten Hoedt Appointed Chair of Coramaze Board to Guide Tripair’s Growth

Team

“Tripair is revolutionary, not only in its ability to simplify TR treatment but also in its potential to fundamentally change how we approach this widespread yet often overlooked condition. The technology addresses key challenges in complexity, cost, and adoption, paving the way for better patient outcomes and broader access to care in established and new markets. I am excited to work with the team to ultimately bring this solution to patients and clinics worldwide.”

We are thrilled to welcome Rob ten Hoedt as the new Chairman of the Board. A seasoned leader in the medical technology space, Rob brings a wealth of experience from his time as Executive Vice President and President of Global Regions at Medtronic, and Chairman of MedTech Europe.

His deep expertise in global commercialization, strategic growth, and medical technology innovation will be instrumental as we advance Tripair™, our minimally invasive tricuspid repair solution for Tricuspid Regurgitation (TR). With Tripair™, we aim to simplify TR treatment—overcoming barriers of complexity, cost, and adoption—and expand access to care for the many patients currently left without effective options.

Rob ten Hoedt on joining Tripair as Chairman of the Board:
Tripair is revolutionary, not only in its ability to simplify TR treatment but also in its potential to fundamentally change how we approach this widespread yet often overlooked condition. The technology addresses key challenges in complexity, cost, and adoption, paving the way for better patient outcomes and broader access to care in established and new markets. I am excited to work with the team to ultimately bring this solution to patients and clinics worldwide.

We are excited for this next chapter as we progress into global feasibility studies—and ultimately towards commercialization and global market entry. Stay tuned for more updates as we work to bring Tripair™ to patients in need!